Yahoo Web Search

Search results

    • John L. Sander

      The National Law Review· 5 days ago

      Before joining the firm, Mr. Sander served in senior in-house roles for more than 16 years at Merck & Co., Inc. and its predecessor, Schering-Plough Corporation. At

    • Pfizer's Stock Is a Buy. Here Are Six Reasons Why.

      Pfizer's Stock Is a Buy. Here Are Six Reasons Why.

      Motley Fool via Yahoo Finance· 11 hours ago

      Prevnar: The pneumococcal vaccine should continue being a cash cow for the drugmaker despite potential competition from Merck's vaccine V116 in the adult...